Tevogen Reports Ongoing Growth in Institutional Ownership for Q2 2025; 72% of Investors Either Increased or Sustained Their Holdings
Institutional Ownership Increase: Tevogen Bio Holdings Inc. reported a 24% increase in institutional ownership of its common stock for the second quarter of 2025, following a 60% increase in the first quarter.
Major Contributors: Morgan Stanley and BlackRock were the largest contributors to this growth, increasing their holdings by 80%, while the number of institutional holders rose from 51 to 55.
Positive Investor Sentiment: Tapan Shah, Head of Investor Relations at Tevogen, indicated that the rise in institutional ownership reflects confidence in the company's scientific progress and operational milestones.
Forward-Looking Statements Caution: The press release included forward-looking statements about Tevogen's future plans and potential risks, emphasizing that actual results may differ due to various uncertainties and challenges.
Trade with 70% Backtested Accuracy
Analyst Views on TVGNW
No data
About the author
TEVOGEN BOARD CONSIDERS POSSIBLE ONE-TIME SPECIAL CASH DIVIDEND FOR SHAREHOLDERS
Evaluation of Special Cash Dividend: The board of Tevogen is set to assess the potential for a one-time special cash dividend for shareholders.
Focus on Shareholder Value: This evaluation indicates a commitment to enhancing shareholder value through potential financial returns.
Tevogen Addresses Financial Report, Emphasizing Robust Capital Efficiency and Minimal Cash Burn
Financial Clarity: Tevogen Bio Holdings Inc. plans to provide a reconciled set of non-GAAP metrics to clarify its financial position, particularly regarding its reported accumulated deficit of $129 million under U.S. GAAP standards.
Cash vs. Non-Cash Expenses: The company has raised under $42 million since its inception, with a total cash loss of approximately $41 million, while the remaining deficit largely consists of non-cash expenses amounting to about $88 million.
Investor Communication: Tevogen aims to enhance investor understanding by distinguishing between cash and non-cash components in its financial results, emphasizing transparency in its reporting.
Forward-Looking Statements: The press release includes forward-looking statements about Tevogen's growth and operational plans, highlighting potential risks and uncertainties that could impact future performance.
Tevogen Executives Connect with Business and Community Leaders to Showcase Recent Achievements
Tevogen's Biopharma Model: Tevogen Bio Holdings Inc. emphasizes its commitment to sustainability and affordability in precision medicine, aiming to make T cell therapies accessible for various diseases, including cancers and Long COVID.
Financial Projections: The company values its first clinical product, TVGN 489, at $9–$11 billion and estimates a potential top-line revenue of approximately $6.5 billion over five years for a product targeting liver cancer prevention.
AI Developments: Tevogen.AI has made significant progress in developing its PredicTcell™ model in collaboration with Microsoft and Databricks, which could lead to substantial cost savings in drug development.
Intellectual Property and Future Outlook: Tevogen has secured multiple patents related to its T cell therapies and AI technologies, while also acknowledging potential risks and uncertainties that could impact its growth and development plans.
Tevogen Provides Update on TVGN 489 Amid Increasing Interest from Long COVID Patients
Collaboration for Development: Tevogen Bio is working with government initiatives, Long COVID patient organizations, and healthcare providers to expedite the development of its investigational therapy, TVGN 489, aimed at treating COVID-19 and Long COVID.
Patient Communication Channel: In response to high patient interest, Tevogen has set up a dedicated communication channel for Long COVID updates, allowing patients to receive verified information as it becomes available.
Tevogen Achieves Significant Progress in AI Efforts to Improve T Cell–Based Therapies with 100x Expansion of PredicTcell™ Beta Data
PredicTcell™ Platform Development: Tevogen Bio has announced the beta version of its PredicTcell™ platform, which has expanded its training dataset to approximately 1.4 million records and a total dataset exceeding 6.7 billion records, enhancing its capabilities in precision immunotherapy through advanced machine learning.
Impact on T Cell Therapies: The advancements in the PredicTcell platform aim to significantly improve the reliability of T cell therapies, potentially increasing clinical success rates, shortening development timelines, and reducing costs, thereby enhancing patient access to life-saving treatments across various diseases.
Tevogen Praises HHS for Tackling Long COVID, Highlights TVGN 489's Potential Benefits for 20 Million Americans
Tevogen's Acknowledgment: Tevogen Bio Holdings expressed gratitude to the U.S. Department of Health and Human Services and the Trump Administration for organizing Long COVID roundtables, highlighting the significant impact of Long COVID on millions of Americans and the economy.
Investigational Drug TVGN 489: The company is optimistic about its investigational drug, TVGN 489, which has shown promising results in clinical trials and aims to address the public health crisis of Long COVID, potentially restoring health for affected individuals.
TEVOGEN BOARD CONSIDERS POSSIBLE ONE-TIME SPECIAL CASH DIVIDEND FOR SHAREHOLDERS
Evaluation of Special Cash Dividend: The board of Tevogen is set to assess the potential for a one-time special cash dividend for shareholders.
Focus on Shareholder Value: This evaluation indicates a commitment to enhancing shareholder value through potential financial returns.
Tevogen Addresses Financial Report, Emphasizing Robust Capital Efficiency and Minimal Cash Burn
Financial Clarity: Tevogen Bio Holdings Inc. plans to provide a reconciled set of non-GAAP metrics to clarify its financial position, particularly regarding its reported accumulated deficit of $129 million under U.S. GAAP standards.
Cash vs. Non-Cash Expenses: The company has raised under $42 million since its inception, with a total cash loss of approximately $41 million, while the remaining deficit largely consists of non-cash expenses amounting to about $88 million.
Investor Communication: Tevogen aims to enhance investor understanding by distinguishing between cash and non-cash components in its financial results, emphasizing transparency in its reporting.
Forward-Looking Statements: The press release includes forward-looking statements about Tevogen's growth and operational plans, highlighting potential risks and uncertainties that could impact future performance.
Tevogen Executives Connect with Business and Community Leaders to Showcase Recent Achievements
Tevogen's Biopharma Model: Tevogen Bio Holdings Inc. emphasizes its commitment to sustainability and affordability in precision medicine, aiming to make T cell therapies accessible for various diseases, including cancers and Long COVID.
Financial Projections: The company values its first clinical product, TVGN 489, at $9–$11 billion and estimates a potential top-line revenue of approximately $6.5 billion over five years for a product targeting liver cancer prevention.
AI Developments: Tevogen.AI has made significant progress in developing its PredicTcell™ model in collaboration with Microsoft and Databricks, which could lead to substantial cost savings in drug development.
Intellectual Property and Future Outlook: Tevogen has secured multiple patents related to its T cell therapies and AI technologies, while also acknowledging potential risks and uncertainties that could impact its growth and development plans.
Tevogen Provides Update on TVGN 489 Amid Increasing Interest from Long COVID Patients
Collaboration for Development: Tevogen Bio is working with government initiatives, Long COVID patient organizations, and healthcare providers to expedite the development of its investigational therapy, TVGN 489, aimed at treating COVID-19 and Long COVID.
Patient Communication Channel: In response to high patient interest, Tevogen has set up a dedicated communication channel for Long COVID updates, allowing patients to receive verified information as it becomes available.
Tevogen Achieves Significant Progress in AI Efforts to Improve T Cell–Based Therapies with 100x Expansion of PredicTcell™ Beta Data
PredicTcell™ Platform Development: Tevogen Bio has announced the beta version of its PredicTcell™ platform, which has expanded its training dataset to approximately 1.4 million records and a total dataset exceeding 6.7 billion records, enhancing its capabilities in precision immunotherapy through advanced machine learning.
Impact on T Cell Therapies: The advancements in the PredicTcell platform aim to significantly improve the reliability of T cell therapies, potentially increasing clinical success rates, shortening development timelines, and reducing costs, thereby enhancing patient access to life-saving treatments across various diseases.
Tevogen Praises HHS for Tackling Long COVID, Highlights TVGN 489's Potential Benefits for 20 Million Americans
Tevogen's Acknowledgment: Tevogen Bio Holdings expressed gratitude to the U.S. Department of Health and Human Services and the Trump Administration for organizing Long COVID roundtables, highlighting the significant impact of Long COVID on millions of Americans and the economy.
Investigational Drug TVGN 489: The company is optimistic about its investigational drug, TVGN 489, which has shown promising results in clinical trials and aims to address the public health crisis of Long COVID, potentially restoring health for affected individuals.
